It's in the exclusion list for very good reason, 1) so to not complicate the trials, 2) the drug will ultimately be licensed for a specific use, otosclerosis is not its intended use.
If the drug is approved and shows a way of reducing bone remodelling in the cochlea, it could be used off-label.